Lu YOU, Peiyi YE, Guanqing XIAO, Jiabao LIANG, Yaozhong KONG

Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis

Background/aim: This meta-analysis comprehensively investigated the efficacy and safety of rituximab (RTX) in patients with idiopathic membranous nephropathy (IMN). Materials and methods: We searched the MEDLINE, EMBASE and Cochrane Registry of Controlled Trials databases from January 2000 to January 2020. Studies evaluating the efficacy and safety of RTX in the treatment of IMN with nephrotic syndrome (NS) were included. Results: Nine studies (total of 357 patients) were included in the meta-analysis. The pooled complete response and overall response (OR) rates at 12 months were 13.2% [95% confidence interval (CI), 0.09–0.18] and 60% (95% CI, 0.48–0.72), and those at 24 months were 27.8% (95% CI, 0.22–0.34) and 66% (95% CI, 0.6–0.72), respectively. The pooled OR rates for the low-, standard-, and high-dose groups were 39.3%, 64%, and 60%, respectively, and those for the first-line and second-line groups were 58% and 54%, respectively. Conclusion: Treatment of IMN with RTX has comparable efficacy to other immunosuppressive treatments (ISTs). RTX has the advantages of no requirement for steroids and lower rates adverse event and relapse rates. Patients who relapse or are resistant to other IST agents also respond to RTX. RTX-based regimens and other B-cell-targeted therapies may represent the future of IMN therapy.Key words: Rituximab, membranous nephropathy, immunosuppressive treatment, meta-analysis

PDF

___

1. Couser WG. Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology 2017; 12 (6):983-997. doi:10.2215/CJN.11761116
2. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T et al. Prognosis of untreated patients with idiopathic membranous nephropathy. New England Journal of Medicine 1993; 329 (2):85-89. doi:10.1056/NEJM199307083290203
3. Tomas NM, Beck LJ, Meyer-Schwesinger C, Seitz-Polski B, Ma H et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. New England Journal of Medicine 2014; 371(24):2277-2287. doi:10.1056/ NEJMoa1409354
4. Beck LJ, Bonegio RG, Lambeau G, Beck DM, Powell DW et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New England Journal of Medicine 2009; 361 (1):11-21. doi:10.1056/NEJMoa0810457
5. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. Journal of the American Society of Nephrology 1998; 9(3):444- 450. doi:10.1681/ASN.V93444
6. Cybulsky AV, Walsh M, Knoll G, Hladunewich M, Bargman J et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults. American Journal of Kidney Diseases 2014; 63(3):363-377. doi:10.1053/j. ajkd.2013.12.001
7. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. The Lancet 2013; 381(9868):744-751. doi:10.1016/S0140-6736(12)61566-9
8. Angioi A, Lepori N, Lopez AC, Sethi S, Fervenza FC et al. Treatment of primary membranous nephropathy: where are we now? Journal of Nephrology 2018; 31(4):489-502. doi:10.1007/ s40620-017-0427-5
9. Salles G, Barrett M, Foa R, Maurer J, O’Brien S et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy 2017; 34(10):2232- 2273. doi:10.1007/s12325-017-0612-x
10. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology 2017;13(9): 563-579. doi:10.1038/ nrneph.2017.92
11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp.
12. Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. American Journal of Nephrology 2011; 33(5):461-468. doi:10.1159/000327611
13. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Nephrology 2017; 28(1):348-358. doi:10.1681/ ASN.2016040449
14. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine 2019; 381(1):36-46. doi:10.1056/NEJMoa1814427
15. Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M et al. High-Dose Rituximab and Early Remission in PLA2R1- Related Membranous Nephropathy. Clinical Journal of the American Society of Nephrology 2019; 14(8):1173-1182. doi:10.2215/CJN.11791018
16. Wang X, Cui Z, Zhang YM, Qu Z, Wang F et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrology Dialysis Transplantation 2018; 33(9):1558-1563. doi:10.1093/ndt/gfx295
17. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney International 2008; 73(1):117-125. doi:10.1038/sj.ki.5002628
18. Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S et al. Lowand high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrology Dialysis Transplantation 2013; 28(1):137-146. doi:10.1093/ndt/gfs379
19. Moroni G, Depetri F, Del VL, Gallelli B, Raffiotta F et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrology Dialysis Transplantation 2017; 32(10):1691-1696. doi:10.1093/ndt/ gfw251
20. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B et al. Rituximab in idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2012; 23(8):1416-1425. doi:10.1681/ASN.2012020181
21. Rojas-Rivera JE, Carriazo S, Ortiz A. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clinical Kidney Journal 2019; 12(5):629-638. doi:10.1093/ckj/sfz127
22. Makker SP, Kanalas JJ. Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. The Journal of Immunology 1989; 142(10):3406-3410.
23. Segarra A, Praga M, Ramos N, Polanco N, Cargol I et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clinical Journal of the American Society of Nephrology 2009; 4(6):1083-1088. doi:10.2215/CJN.06041108
24. Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, et al. Rituximab use in adult glomerulopathies and its rationale. Brazilian Journal of Nephrology 2019; 42:77-93. doi:10.1590/2175-8239- JBN-2018-0254